{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:15:21Z","timestamp":1784211321591,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05481-4","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T09:23:34Z","timestamp":1782033814000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Toxicity outcomes of concurrent radiotherapy with adjuvant capecitabine in triple-negative breast cancer (TROD 06-24)"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9632-180X","authenticated-orcid":false,"given":"Volkan","family":"Demircan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berrin","family":"Benli Yavuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bekir Hakan","family":"Bakkal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukran","family":"Celikarslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sule","family":"Karabulut Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huseyin","family":"Tepetam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didem","family":"Colpan Oksuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaettin","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse","family":"Altinok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,21]]},"reference":[{"key":"5481_CR1","doi-asserted-by":"publisher","first-page":"836417","DOI":"10.3389\/fmolb.2022.836417","volume":"9","author":"NM Almansour","year":"2022","unstructured":"Almansour NM. Triple-negative breast cancer: a brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence. Front Mol Biosci. 2022;9:836417. https:\/\/doi.org\/10.3389\/fmolb.2022.836417.","journal-title":"Front Mol Biosci"},{"issue":"21","key":"5481_CR2","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, K\u00fcmmel S, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med. 2024;391(21):1981\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2409932.","journal-title":"N Engl J Med"},{"issue":"8","key":"5481_CR3","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194\u2013220. https:\/\/doi.org\/10.1093\/annonc\/mdz173.","journal-title":"Ann Oncol"},{"issue":"1","key":"5481_CR4","doi-asserted-by":"publisher","first-page":"13977","DOI":"10.1038\/s41598-025-98176-9","volume":"15","author":"SY Lee","year":"2025","unstructured":"Lee SY, Yoo TK, Lee SB, Kim J, Chung IY, Ko BS, et al. Prognostic value of residual cancer burden after neoadjuvant chemotherapy in breast cancer: a comprehensive subtype-specific analysis. Sci Rep. 2025;15(1):13977. https:\/\/doi.org\/10.1038\/s41598-025-98176-9.","journal-title":"Sci Rep"},{"issue":"22","key":"5481_CR5","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147\u201359. https:\/\/doi.org\/10.1056\/NEJMoa1612645.","journal-title":"N Engl J Med"},{"issue":"23","key":"5481_CR6","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1200\/JCO.21.00976","volume":"39","author":"IA Mayer","year":"2021","unstructured":"Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, et al. Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131. J Clin Oncol. 2021;39(23):2539\u201351. https:\/\/doi.org\/10.1200\/JCO.21.00976.","journal-title":"J Clin Oncol"},{"issue":"10","key":"5481_CR7","first-page":"2948","volume":"5","author":"N Sawada","year":"1999","unstructured":"Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 1999;5(10):2948\u201353. PMID: 10537364.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"5481_CR8","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.ijrobp.2011.05.027","volume":"82","author":"SJ Wong","year":"2012","unstructured":"Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, et al. Radiation Therapy Oncology Group 0247: a randomized phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2012;82(4):1367\u201375. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.05.027.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"22","key":"5481_CR9","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2016.67.5561","volume":"34","author":"EP Balaban","year":"2016","unstructured":"Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(22):2654\u201368. https:\/\/doi.org\/10.1200\/JCO.2016.67.5561.","journal-title":"J Clin Oncol"},{"issue":"24","key":"5481_CR10","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","volume":"33","author":"E Ben-Josef","year":"2015","unstructured":"Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33(24):2617\u201322. https:\/\/doi.org\/10.1200\/JCO.2014.60.2219.","journal-title":"J Clin Oncol"},{"issue":"3","key":"5481_CR11","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s11604-010-0537-7","volume":"29","author":"H Hirowatari","year":"2011","unstructured":"Hirowatari H, Karasawa K, Izawa H, Ito K, Sasai K, Furuya T, et al. Full-dose capecitabine with local radiotherapy: one of the treatment options for inoperable T4 breast cancer. Jpn J Radiol. 2011;29(3):222\u20135. https:\/\/doi.org\/10.1007\/s11604-010-0537-7.","journal-title":"Jpn J Radiol"},{"issue":"1","key":"5481_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/01.coc.0000245475.41324.6d","volume":"30","author":"MF Gaui","year":"2007","unstructured":"Gaui MF, Amorim G, Arcuri RA, Pereira G, Moreira D, Djahjah C, et al. A phase II study of second-line neoadjuvant chemotherapy with capecitabine and radiation therapy for anthracycline-resistant locally advanced breast cancer. Am J Clin Oncol. 2007;30(1):78\u201381. https:\/\/doi.org\/10.1097\/01.coc.0000245475.41324.6d.","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"5481_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ijrobp.2017.04.030","volume":"99","author":"WA Woodward","year":"2017","unstructured":"Woodward WA, Fang P, Arriaga L, Gao H, Cohen EN, Reuben JM, et al. A phase 2 study of preoperative capecitabine and concomitant radiation in women with advanced breast cancer. Int J Radiat Oncol Biol Phys. 2017;99(4):777\u201383. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.04.030.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"5481_CR14","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ijrobp.2017.08.002","volume":"99","author":"AB Chakravarthy","year":"2017","unstructured":"Chakravarthy AB. Neoadjuvant chemoradiation in the treatment of locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 2017;99(4):784\u20136. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.08.002.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"5481_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.clbc.2020.02.010","volume":"20","author":"AD Sherry","year":"2020","unstructured":"Sherry AD, Mayer IA, Ayala-Peacock DN, Abramson VG, Rexer BN, Chakravarthy AB. Combining adjuvant radiotherapy with capecitabine in chemotherapy-resistant breast cancer: feasibility, safety, and toxicity. Clin Breast Cancer. 2020;20(4):344\u2013e3521. https:\/\/doi.org\/10.1016\/j.clbc.2020.02.010.","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"5481_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ijrobp.2024.11.109","volume":"122","author":"N Kim","year":"2025","unstructured":"Kim N, Kim SS, Cho WK, Park W, Chang JH, Kim YB, et al. Concurrent versus sequential adjuvant capecitabine-based chemoradiation in residual triple-negative breast cancer after neoadjuvant chemotherapy: a multicenter comparative study. Int J Radiat Oncol Biol Phys. 2025;122(1):72\u201383. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.11.109.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"5481_CR17","doi-asserted-by":"publisher","first-page":"e345","DOI":"10.1016\/j.ijrobp.2024.07.761","volume":"120","author":"C Zhu","year":"2024","unstructured":"Zhu C, Zhai Y, Lan B, Xuan L, Zhou L, Liu Y, et al. Safety of concurrent capecitabine and radiotherapy in breast cancer patients: a real-world analysis. Int J Radiat Oncol Biol Phys. 2024;120(2):e345\u20136. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.07.761.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5481_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.7150\/oncm.17910","volume":"2","author":"U Goyal","year":"2017","unstructured":"Goyal U, Skrepnik T, Davuluri R, Ley MB, Chalasani P, Viscusi RK, et al. Concurrent capecitabine and radiation therapy for high-risk primary breast cancer. Oncomedicine. 2017;2:61\u20135. https:\/\/doi.org\/10.7150\/oncm.17910.","journal-title":"Oncomedicine"},{"issue":"13","key":"5481_CR19","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1200\/JCO.2002.20.13.3029","volume":"20","author":"E Ortmann","year":"2002","unstructured":"Ortmann E, Hohenberg G. Treatment side effects: case 1. Radiation recall phenomenon after administration of capecitabine. J Clin Oncol. 2002;20(13):3029\u201330. https:\/\/doi.org\/10.1200\/JCO.2002.20.13.3029.","journal-title":"J Clin Oncol"},{"issue":"8","key":"5481_CR20","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/annonc\/mdg346","volume":"14","author":"P Reichardt","year":"2003","unstructured":"Reichardt P, von Minckwitz G, Thuss-Patience PC, Jonat W, K\u00f6lbl H, J\u00e4nicke F, et al. Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol. 2003;14(8):1227\u201333. https:\/\/doi.org\/10.1093\/annonc\/mdg346.","journal-title":"Ann Oncol"},{"key":"5481_CR21","doi-asserted-by":"publisher","first-page":"100403","DOI":"10.1016\/j.ctarc.2021.100403","volume":"28","author":"T Behroozian","year":"2021","unstructured":"Behroozian T, Milton L, Li N, Zhang L, Lou J, Karam I, et al. Predictive factors associated with radiation dermatitis in breast cancer. Cancer Treat Res Commun. 2021;28:100403. https:\/\/doi.org\/10.1016\/j.ctarc.2021.100403.","journal-title":"Cancer Treat Res Commun"},{"issue":"1","key":"5481_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.adro.2017.10.007","volume":"3","author":"A Parekh","year":"2017","unstructured":"Parekh A, Dholakia AD, Zabransky DJ, Asrari F, Camp M, Habibi M, et al. Predictors of radiation-induced acute skin toxicity in breast cancer at a single institution: role of fractionation and treatment volume. Adv Radiat Oncol. 2017;3(1):8\u201315. https:\/\/doi.org\/10.1016\/j.adro.2017.10.007.","journal-title":"Adv Radiat Oncol"},{"key":"5481_CR23","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1186\/1471-2407-10-508","volume":"10","author":"MF Chen","year":"2010","unstructured":"Chen MF, Chen WC, Lai CH, Hung CH, Liu KC, Cheng YH. Predictive factors of radiation-induced skin toxicity in breast cancer patients. BMC Cancer. 2010;10:508. https:\/\/doi.org\/10.1186\/1471-2407-10-508.","journal-title":"BMC Cancer"},{"issue":"11","key":"5481_CR24","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","volume":"14","author":"JS Haviland","year":"2013","unstructured":"Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086\u201394. https:\/\/doi.org\/10.1016\/S1470-2045(13)70386-3.","journal-title":"Lancet Oncol"},{"issue":"6","key":"5481_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa0906260","volume":"362","author":"TJ Whelan","year":"2010","unstructured":"Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513\u201320. https:\/\/doi.org\/10.1056\/NEJMoa0906260.","journal-title":"N Engl J Med"},{"issue":"7","key":"5481_CR26","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1001\/jamaoncol.2015.2666","volume":"1","author":"SF Shaitelman","year":"2015","unstructured":"Shaitelman SF, Schlembach PJ, Arzu I, Ballo M, Bloom ES, Buchholz D, et al. Acute and short-term toxic effects of conventionally fractionated vs hypofractionated whole-breast irradiation: a randomized clinical trial. JAMA Oncol. 2015;1(7):931\u201341. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2666.","journal-title":"JAMA Oncol"},{"key":"5481_CR27","doi-asserted-by":"publisher","first-page":"753209","DOI":"10.3389\/fonc.2021.753209","volume":"11","author":"L Gu","year":"2021","unstructured":"Gu L, Dai W, Fu R, Lu H, Shen J, Shi Y, Zhang M, Jiang K, Wu F. Comparing Hypofractionated With Conventional Fractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. Front Oncol. 2021;11:753209. https:\/\/doi.org\/10.3389\/fonc.2021.753209.","journal-title":"Front Oncol"},{"issue":"2","key":"5481_CR28","doi-asserted-by":"publisher","first-page":"325","DOI":"10.4103\/1110-2098.163881","volume":"28","author":"AM Alhanafy","year":"2015","unstructured":"Alhanafy AM, Abd El-Ghany AE, Shaltout EA, El-Fetouh MA, Hashem TA. Safety and feasibility of concurrent capecitabine and hypofractionated postmastectomy radiotherapy. Menoufia Med J. 2015;28(2):325\u201332. https:\/\/doi.org\/10.4103\/1110-2098.163881.","journal-title":"Menoufia Med J"},{"issue":"1","key":"5481_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00066-020-01667-z","volume":"197","author":"MD Piroth","year":"2021","unstructured":"Piroth MD, Krug D, Sedlmayer F, Baumann R, Budach W, Dunst J, et al. Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients\u2014sequentially, or better simultaneously? Strahlenther Onkol. 2021;197(1):1\u20137. https:\/\/doi.org\/10.1007\/s00066-020-01667-z.","journal-title":"Strahlenther Onkol"},{"issue":"5","key":"5481_CR30","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.breast.2005.06.007","volume":"14","author":"L El-Helw","year":"2005","unstructured":"El-Helw L, Coleman RE. Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer. Breast. 2005;14(5):368\u201374. https:\/\/doi.org\/10.1016\/j.breast.2005.06.007.","journal-title":"Breast"},{"issue":"1","key":"5481_CR31","doi-asserted-by":"publisher","first-page":"e2400068","DOI":"10.1200\/OA-24-00068","volume":"2","author":"QJ Khan","year":"2025","unstructured":"Khan QJ, Bohnenkamp C, Monson TE, Phadnis MA, Clark L, Smith HE, et al. Randomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7\/7 Trial. JCO Oncol Adv. 2025;2(1):e2400068. https:\/\/doi.org\/10.1200\/OA-24-00068.","journal-title":"JCO Oncol Adv"},{"issue":"13","key":"5481_CR32","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1200\/JCO-25-02896","volume":"44","author":"MJ Ratain","year":"2026","unstructured":"Ratain MJ, O\u2019Donnell PH. Dear doctor: we still have no idea of what dose of capecitabine you should prescribe. J Clin Oncol. 2026;44(13):1186\u20139. https:\/\/doi.org\/10.1200\/JCO-25-02896.","journal-title":"J Clin Oncol"},{"issue":"16","key":"5481_CR33","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/sim.1047","volume":"21","author":"G Heinze","year":"2002","unstructured":"Heinze G, Schemper M. A solution to the problem of separation in logistic regression. Stat Med. 2002;21(16):2409\u201319. https:\/\/doi.org\/10.1002\/sim.1047.","journal-title":"Stat Med"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05481-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05481-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05481-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:01:57Z","timestamp":1784210517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05481-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,21]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5481"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05481-4","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,21]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval for this study was obtained from the Bah\u00e7e\u015fehir University Non-Interventional Studies Ethics Committee (Approval No: 2025-14\/07). All procedures involving human participants were conducted in accordance with the ethical standards of the institutional and\/or national research committee and with the principles of the Declaration of Helsinki and its later amendments. Informed consent was obtained from all individual participants included in the study. Patients provided written informed consent prior to their inclusion in the study, in accordance with institutional requirements and applicable ethical guidelines.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1028"}}